All In MedTech

FDA Clearance Tracker · P140029-S058

Restylane® Contour

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 18, 2026

Approved

Time to decision

120 days

Received May 21, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P140029-S058
Device name
Restylane® Contour
Applicant
Q-Med AB
Applicant location
Uppsala
Received
May 21, 2026
Decided
Sep 18, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P140029

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

approval for updated device labeling, including the addition of a statement regarding how the Restylane Contour is only for distribution to providers that have taken and successfully completed device-specific use training program when used for the correction of temple hollowing in patients over the age of 21.

Source documents

Other decisions for Q-Med AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.